A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Conditions

Lymphoid Leukemia

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

Find out more about who can participate in this trial

Trial with
Incyte Corporation
Start Date
04/20/2018
End Date
02/01/2024

For more information about this study, contact:

Sharon Huie

sharon.huie@yale.edu

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Farzana Pashankar, MD, MRCP, MBBS
Professor of Pediatrics (Hematology/Oncology); Fellowship Director, Pediatric Hematology & Oncology Program; Director, Solid Tumor Program, Pediatric Hematology & Oncology Program; Children's Oncology Group Site PI, Pediatric Hematology & Oncology Program

Sub-Investigators

Last Updated
11/11/2022
Study HIC
#1606018018

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information